Mélanie Thill-Tayara
Dechert (Paris)
Partner
Mélanie Thill-Tayara is a partner in Dechert’s Paris office and co-lead of the firm’s Life Sciences practice. Mélanie focuses her practice on antitrust and competition law, and she regularly represents leading companies in cartel and abuse of dominant position cases before EU and French authorities and courts. In addition, Mélanie assists leading companies in merger notifications before the French and European regulators and coordinates multi-jurisdictional filings. She regularly advises clients involved in inspections conducted by the authorities and the subsequent challenges. Prior to joining Dechert in February 2016, she served as a partner for more than 20 years with two other international law firms. Before that, she was an officer at the European Commission, Directorate-General for Competition, where she participated in numerous dawn raid operations and contributed to several decisions. Named Top Woman in Antitrust (GCR Women in Antitrust), Mélanie Thill-Tayara is ranked as one of the top competition and antitrust lawyers in France by Chambers Europe, Legal 500, GCR100, Who’s Who Legal : France and Best Lawyers France 2022.
Distinctions
Auteurs associés
Beverly J. Ang
Dechert (New York)
Laure Arnaud
Dechert (Paris)
Laurence Bary
Dechert (Paris)
Maryana Batalova
Dechert (Moscow)
Steven E. Bizar
Dechert (Philadelphia)
39054 | Évènements
Articles
8153 Bulletin
43
On 1 June 2022, the French Supreme Court (the “Supreme Court”) entirely dismissed the appeal of Janssen-Cilag (“Janssen”) and its parent company Johnson & Johnson against a judgment of the Paris Court of Appeal (the “Court of Appeal”) of 11 July 2019 in the Durogesic® case. However, this ruling (...)
1069
In a communication of November 2020, the European Commission presented its ‘new Pharmaceutical Strategy for Europe’, the main objective of which is to achieve a strong, fair, competitive, and green pharmaceutical industry, centered on patients’ needs. The Commission’s ambition is to remove existing barriers that prevent patients’ access to innovative and affordable medicines, while facilitating the digital transformation of the industry. In this context, the enforcement of competition rules certainly remains an important instrument for the Commission to achieve its goals and we expect the sector to remain a key priority throughout the European Union. Just in the past year, several important decisions have been adopted and multiple investigations opened, both in antitrust and merger control.
175
The European Court of Justice has confirmed that financial investors can incur parental liability for the anticompetitive practices of portfolio companies, even after an IPO that left the investor holding only a minority stake in the company, provided that they still have sufficient (...)
22
This article has been nominated for the 2021 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The European Court of Justice has confirmed that financial investors can incur parental liability for the anticompetitive practices of portfolio companies, even (...)
4567
While pharmaceutical companies are subject to sector-specific regulations, the industry is not exempt from competition law, as exemplified by the numerous investigations that are regularly conducted by competition authorities around the globe and the magnitude of the sanctions that have been levied on pharmaceutical companies in recent years.
208
In three recent judgments issued on 5 October 2020, the General Court of the European Union ("GCEU") partially annulled the European Commission’s ("Commission") decisions of February 2017 which had authorized onsite unannounced inspections ("dawn raid”) to be carried out at the headquarters of (...)
496
Key Takeaways Following several individual initiatives by member state competition authorities to temporarily relax competition rules in specific sectors, the European Competition Network (which includes the European Commission and all member state competition authorities) has issued a more (...)
152
On 14 November 2019, the Paris Court of Appeal (the “Court”) quashed a decision of the French Competition Authority (“FCA”) of 20 September 2018 in which the latter had imposed € 199 000 fine on Sanicorse for having abused its dominant position on the market for infectious clinical waste (“ICW”) (...)
124
More particularly, the Court affirmed the FCA’s conclusion that Janssen infringed competition law by, on the one hand, disparaging competing fentanyl specialties towards health professionals, emphasizing the risks associated with a switch from Durogesic© to a generic version and, on the other (...)
532
The General Court annuls in part the European Commission’s decision finding the existence of restrictive agreements and an abuse of a dominant position on the market for perindopril, a medicine used to treat hypertension and heart failure* On 12 December 2018, the General Court (“Court”) (...)
163
The General Court of the European Union recently held, in Goldman Sachs v. Commission, that purely financial investors such as investment funds may be held jointly and severally liable for competition law violations implemented by their portfolio companies when they can exercise “decisive (...)
250
EU Court Orders New Assessment of Intel’s Rebates The Court of Justice of the European Union (CJEU) has quashed a ruling by the EU’s General Court which had upheld the European Commission’s (EC) 2009 finding of abuse of dominance by Intel Corporation Inc. Intel was fined €1.06 billion, a record at (...)
352
This article has been nominated for the 2015 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The new “Hamon Law” introducing French class actions and its effects on competition and distribution law Introduction In order to balance the powers of economic (...)
9621 Revue
3679
Quel bilan concurrentiel pour Emmanuel Macron, Ministre de l’Economie puis Président de la République ? Il est remarquable qu’Emmanuel Macron a eu une volonté réformatrice très forte en droit de la concurrence, et de la distribution, en ouvrant les marchés (professions réglementées, transport par car, (...)
1502
La Cour de justice rendait en 2021 un arrêt important pour le Private enforcement en Europe. Elle considérait que le demandeur de dommages intérêts dans le cadre d’une action consécutive à la sanction d’un cartel peut assigner en justice la filiale de l’auteur de l’infraction. Pour arriver à cette (...)
690
Les présentes contributions ont été rassemblées à la suite de la 10ème édition de la conférence annuelle “Demain la concurrence” organisée par la Revue Concurrences le 14 juin 2019, au Ministère de l’Économie et des Finances à Paris. Les débats s’organisaient autour de quatre thèmes. Les membres de la (...)
372
La procédure d’engagements présente un intérêt certain pour les entreprises suspectées d’avoir enfreint le droit de la concurrence, qui évitent ainsi une investigation approfondie et une potentielle amende. Du point de vue des autorités de concurrence, elle constitue également un outil efficace (...)
1228
Interview réalisée par Mélanie Thill-Tayara, Associée, Dechert, Paris. Diplômé de l’Institut d’études politiques de Paris et de l’ENA, vous avez occupé plusieurs postes au sein de la DGCCRF, travaillé pour la Représentation permanente de la France auprès de l’Union européenne et, moins classique, avez (...)
1289
Ce dossier réunit 3 contributions sur les développements récents dans le secteur pharmaceutique. Pour Me Thill-Tayara, avocate chez Dechert Paris et auteur de la première contribution, si l’activisme des autorités de concurrence est motivé, au moins en partie, par le besoin de limiter les dépenses des (...)
861
La troisième table-ronde de la conférence “Demain la concurrence” du 21 février 2014 à Paris, était dédiée au “Règlement 1/2003 et Réseau européen de concurrence 10 ans après : Faut-il étendre la cooperation au contrôle des concentrations et à l’advocacy ?”. Les objectifs pour les auteurs de cette table ronde (...)
Livres
Prix
290€00
Competition Case Law Digest 5th Edition - A Synthesis of US, EU and National Leading Cases
Date
30 mars 2022
Prix
290€00
Prix
290€00
2020 Competition Case Law Digest - A Synthesis of EU, US and National Leading Cases
Date
31 janvier 2020
Prix
290€00
Dictionnaire de droit de la concurrence
Définitions de l’auteur
